Toru Mukohara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Toru Mukohara has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
Ako Hosono
16 shared publications- Kenichi Harano
Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
16 shared publications - Hiroshi Tanabe
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
13 shared publications Kenichi Harano
Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
13 shared publications- Masashi Wakabayashi
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
12 shared publications - Yoichi Naito
Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan
12 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer
Yokosu K, et al. J Gynecol Oncol. 2027 ;38:e30. https://doi.org/10.3802/jgo.2027.38.e30
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessChanges and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer
Yokosu K, et al. J Gynecol Oncol. 2027 ;38:e30. https://doi.org/10.3802/jgo.2027.38.e30
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis
Onishi J, et al. J Gynecol Oncol. 2027 ;38:e7. https://doi.org/10.3802/jgo.2027.38.e7
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessOutcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis
Onishi J, et al. J Gynecol Oncol. 2027 ;38:e7. https://doi.org/10.3802/jgo.2027.38.e7
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose:Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods:Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results:The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions:Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose:Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods:Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results:The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions:Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.